Novartis takes option on NASH drug from Conatus

Novartis has signalled its strong intentions in the race to develop a treatment for the fatty liver disease, non-alcoholic steatohepatitis (NASH), taking an option on Conatus Pharmaceutical

The liver is a vital organ of the digestive system present in vertebrates and some other animals. It has a wide range of functions, including detoxification, protein synthesis, and production of biochemicals necessary for digestion.

Intercept's liver drug gets green light from NICE

NICE has recommended regular NHS funding for Intercept’s Ocaliva for the chronic liver disease primary biliary cholangitis (PBC) in final draft guidance, providing an alternative option for